诺诚健华(09969)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

09969 诺诚健华

休市中 04-19 16:08:35

4.060

-0.250

-5.80%

最高4.300	最低4.030	成交量544.29万
今开4.280	昨收4.310	日振幅6.26%
总市值71.56亿	流通市值71.56亿	总股本17.63亿
成交额2,232万	换手率0.31%	流通股本17.63亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"09969","market":"HK","secType":"STK","nameCN":"诺诚健华","latestPrice":4.06,"timestamp":1713514115038,"preClose":4.31,"halted":0,"volume":5442935,"delay":0,"floatShares":1762582452,"shares":1762582452,"eps":-0.39957067,"marketStatus":"休市中","marketStatusCode":7,"change":-0.25,"latestTime":"04-19 16:08:35","open":4.28,"high":4.3,"low":4.03,"amount":22320650,"amplitude":0.062645,"askPrice":4.08,"askSize":61000,"bidPrice":4.06,"bidSize":83000,"shortable":3,"etf":0,"ttmEps":-0.39957067562593485,"exchange":"SEHK","tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1713749400000},"adr":0,"listingDate":1584892800000,"adjPreClose":4.31,"openAndCloseTimeList":[[1713490200000,1713499200000],[1713502800000,1713513600000]],"volumeRatio":0.6420288145331657,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"688428","market":"SH","secType":"STK","nameCN":"诺诚健华","latestPrice":7.66,"timestamp":1713510000000,"preClose":7.89,"halted":0,"volume":2733530,"delay":0,"premium":"-50.92"}},"requestUrl":"/m/hq/s/09969","defaultTab":"news","newsList":[{"id":"2428508948","title":"诺诚健华盘中异动 大幅下跌5.10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2428508948","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2428508948?lang=zh_cn&edition=full","pubTime":"2024-04-19 11:03","pubTimestamp":1713495812,"startTime":"0","endTime":"0","summary":"2024年04月19日早盘11时03分，诺诚健华股票出现异动，股价急速下挫5.10%。截至发稿，该股报4.090港元/股，成交量152.694万股，换手率0.10%，振幅4.87%。诺诚健华股票所在的生物技术行业中，整体跌幅为1.22%。其相关个股中，创胜集团-B、三叶草生物-B、帝王国际投资涨幅较大，振幅较大的相关个股有三叶草生物-B、创胜集团-B、乐普生物-B，振幅分别为12.70%、12.50%、9.30%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024041911033287e820a1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024041911033287e820a1&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2428551448","title":"诺诚健华04月18日主力资金流入327万元 连续3日加仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2428551448","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2428551448?lang=zh_cn&edition=full","pubTime":"2024-04-18 16:15","pubTimestamp":1713428154,"startTime":"0","endTime":"0","summary":"04月18日, 诺诚健华股价跌3.58%，报收4.31元，成交金额2713万元，换手率0.42%，振幅4.70%，量比0.81。诺诚健华今日主力资金净流入327万元，连续3日净流入，上一交易日主力净流入141万元，今日环比增加131.91%。近一年数据显示，该股主力连续3日净流入后，次日上涨概率为33.33%，平均涨幅为1.23%。该股近5个交易日下跌11.86%，主力资金累计净流入589万元，其中1个交易日为股价上涨时净流出；近20日主力资金累计净流入79万元，其中净流入天数为7日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404181616208b34bdb6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404181616208b34bdb6&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2427186950","title":"诺诚健华(09969)下跌5.0%，报4.75元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2427186950","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2427186950?lang=zh_cn&edition=full","pubTime":"2024-04-15 10:01","pubTimestamp":1713146517,"startTime":"0","endTime":"0","summary":"4月15日，诺诚健华(09969)盘中下跌5.0%，截至10:01，报4.75元/股，成交242.62万元。诺诚健华医药有限公司是一家拥有一体化生物医药平台的领先企业，主要从事研发治疗癌症和自身免疫性疾病的创新药物。公司具备强大的内部研发能力和世界级管理团队，同时拥有均衡的管线组合和针对经过验证或新颖生物通路的候选药物。截至2023年年报，诺诚健华营业总收入7.39亿元、净利润-6.31亿元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/04/15100140236354.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2425067730","title":"诺诚健华(9969.HK)：业绩符合预期 多产品即将提交NDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2425067730","media":"国泰君安","top":-1,"share":"https://www.laohu8.com/m/news/2425067730?lang=zh_cn&edition=full","pubTime":"2024-04-08 08:01","pubTimestamp":1712534501,"startTime":"0","endTime":"0","summary":"本报告导读：2023 年奥布替尼营收6.71 亿元，血液瘤、自免、实体瘤临床进展顺利，2024 年多款药物有望提交NDA，看好公司未来发展，维持“增持”评级。公司公告 2023年收入 7.39 亿，同比增长 18.1%；净亏损6.31 亿元，同比减亏2.56 亿元。奥布替尼快速放量，多适应症今年内有望递交NDA。④ICP-723 的晚期实体瘤注册临床试验加速推进，预计2024 年底或2025 年初递交NDA。⑤ICP-189联合三代EGFR 抑制剂伏美替尼治疗晚期实体瘤完成首例患者入组，预计2024 年获得PoC。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404080801448afc3db8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404080801448afc3db8&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2425062370","title":"诺诚健华盘中异动 早盘股价大跌5.11%报4.640港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2425062370","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2425062370?lang=zh_cn&edition=full","pubTime":"2024-04-05 10:01","pubTimestamp":1712282474,"startTime":"0","endTime":"0","summary":"2024年04月05日早盘10时01分，诺诚健华股票出现异动，股价急速跳水5.11%。截至发稿，该股报4.640港元/股，成交量17.3万股，换手率0.01%，振幅5.32%。资金方面，该股资金流入13.634万港元，流出51.935万港元。诺诚健华股票所在的生物技术行业中，整体跌幅为1.19%。该信息摘要如下：近日， 诺诚健华 发布2023年年度报告。去年，诺诚健华的整体业绩良好，其自主研发的首款商业化拳头产品奥布替尼可谓功不可没。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240405100115791ed36a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240405100115791ed36a&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2425377441","title":"南向资金4月3日净买入诺诚健华15.10万股 连续3日增持","url":"https://stock-news.laohu8.com/highlight/detail?id=2425377441","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2425377441?lang=zh_cn&edition=full","pubTime":"2024-04-05 09:30","pubTimestamp":1712280624,"startTime":"0","endTime":"0","summary":"4月3日, 南向资金增持诺诚健华15.10万股，连续3日增持。截止当日收盘，港股通共持有诺诚健华21904.49万股，占流通股12.42%。港股通增持金额前五个股分别为腾讯控股、小米集团-W、工商银行、中国银行、理想汽车-W。诺诚健华近5个交易日上涨1.24%，港股通累计增持170.10万股；近20个交易日下跌5.23%，港股通累计增持744.60万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404050932568af288a7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404050932568af288a7&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2424889318","title":"寻找医药新质生产力：从诺诚健华（9969.HK/688428.SH）看本土创新药企高质量发展","url":"https://stock-news.laohu8.com/highlight/detail?id=2424889318","media":"格隆汇","top":-1,"share":"https://www.laohu8.com/m/news/2424889318?lang=zh_cn&edition=full","pubTime":"2024-04-03 08:27","pubTimestamp":1712104040,"startTime":"0","endTime":"0","summary":"诺诚健华作为本土创新药企的代表，可谓成为高质量发展的优质样本。","market":"sg","thumbnail":"https://img2.gelonghui.com/aaa26-063bf2a0-83fb-4931-b0a7-358d85f90af8.jpg?guru_height=2160&guru_width=3840","type":0,"news_type":0,"thumbnails":["https://img2.gelonghui.com/aaa26-063bf2a0-83fb-4931-b0a7-358d85f90af8.jpg?guru_height=2160&guru_width=3840"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/715588","is_publish_highlight":false,"gpt_icon":0},{"id":"2424705395","title":"诺诚健华(09969)上涨5.38%，报4.9元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2424705395","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2424705395?lang=zh_cn&edition=full","pubTime":"2024-04-02 13:07","pubTimestamp":1712034475,"startTime":"0","endTime":"0","summary":"4月2日，诺诚健华(09969)盘中上涨5.38%，截至13:07，报4.9元/股，成交642.1万元。诺诚健华医药有限公司是一家拥有一体化生物医药平台的领先企业，主要从事研发治疗癌症和自身免疫性疾病的创新药物。公司具备强大的内部研发能力和世界级管理团队，同时拥有均衡的管线组合和针对经过验证或新颖生物通路的候选药物。截至2023年年报，诺诚健华营业总收入7.39亿元、净利润-6.31亿元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/04/02130740090636.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2424058221","title":"诺诚健华盘中异动 下午盘急速上涨5.38%","url":"https://stock-news.laohu8.com/highlight/detail?id=2424058221","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2424058221?lang=zh_cn&edition=full","pubTime":"2024-04-02 13:07","pubTimestamp":1712034468,"startTime":"0","endTime":"0","summary":"2024年04月02日下午盘13时07分，诺诚健华股票出现异动，股价快速上涨5.38%。截至发稿，该股报4.901港元/股，成交量133.899万股，换手率0.09%，振幅4.73%。诺诚健华股票所在的生物技术行业中，整体跌幅为0.35%。该信息摘要如下：据证券之星公开数据整理，近期诺诚健华发布2023年年报。根据财报显示，本报告期中诺诚健华营收上升亏损收窄，盈利能力上升。截至本报告期末，公司营业总收入7.39亿元，同比上升18.09%，归母净利润-6.31亿元，同比上升28.8%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240402130748861e2e97&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240402130748861e2e97&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2424519760","title":"诺诚健华宣布SHP2抑制剂ICP-189联合EGFR抑制剂伏美替尼临床研究完成首例患者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2424519760","media":"证券日报","top":-1,"share":"https://www.laohu8.com/m/news/2424519760?lang=zh_cn&edition=full","pubTime":"2024-04-01 17:10","pubTimestamp":1711962620,"startTime":"0","endTime":"0","summary":"3月29日，诺诚健华（港交所代码：09969；上交所代码：688428）宣布，新型蛋白酪氨酸磷酸酶SHP2变构抑制剂ICP-189联合针对表皮生长因子受体（EGFR）突变的口服EGFR激酶抑制剂伏美替尼治疗晚期或转移性非小细胞肺癌（NSCLC）临床1b期研究在中国完成首例患者给药。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202404013031367913.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2423022126","title":"《公司业绩》诺诚健华(09969.HK)全年亏损收窄至6.31亿人民币","url":"https://stock-news.laohu8.com/highlight/detail?id=2423022126","media":"阿斯达克财经","top":-1,"share":"https://www.laohu8.com/m/news/2423022126?lang=zh_cn&edition=full","pubTime":"2024-03-31 21:03","pubTimestamp":1711890180,"startTime":"0","endTime":"0","summary":"诺诚健华(09969.HK) 公布2023年止年度业绩，收益录得7.39亿人民币(下同)，按年增加18.1%。亏损由上年度8.87亿元，收窄至6.31亿元，每股亏损37分。不派末期息。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2024-03-28 16:25。)过往派息公布日期派息事项派息内容2023/11/13第三季业绩无派息2023/08/29中期业绩无派息2023/05/09第一季业绩无派息 2023/03/27末期业绩无派息 AASTOCKS新闻","market":"us","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20200917152906536_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20200917152906536_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1338808/latest-news/AAFN","is_publish_highlight":false,"gpt_icon":0},{"id":"2423447325","title":"诺诚健华（688428）2023年年报简析：营收上升亏损收窄，盈利能力上升","url":"https://stock-news.laohu8.com/highlight/detail?id=2423447325","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2423447325?lang=zh_cn&edition=full","pubTime":"2024-03-30 07:21","pubTimestamp":1711754515,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期诺诚健华发布2023年年报。根据财报显示，本报告期中诺诚健华营收上升亏损收窄，盈利能力上升。截至本报告期末，公司营业总收入7.39亿元，同比上升18.09%，归母净利润-6.31亿元，同比上升28.8%。重仓诺诚健华的前十大基金见下表：持有诺诚健华最多的基金为鹏华医药科技股票A，目前规模为29.78亿元，最新净值1.078，较上一交易日上涨0.47%，近一年下跌4.03%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024033000011050.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2423063488","title":"诺诚健华2023年毛利同比上涨26.6% 亏损同比收窄","url":"https://stock-news.laohu8.com/highlight/detail?id=2423063488","media":"证券日报","top":-1,"share":"https://www.laohu8.com/m/news/2423063488?lang=zh_cn&edition=full","pubTime":"2024-03-29 12:17","pubTimestamp":1711685827,"startTime":"0","endTime":"0","summary":"本报记者李乔宇3月28日晚间，诺诚健华发布截至2023年12月31日的2023年业绩报。去年诺诚健华实现营业收入7.4亿元，同比上涨18.1%。其中奥布替尼收入同比增长18.5%，达到6.7亿元。2023年，诺诚健华实现毛利6.1亿元，同比上涨26.6%；2023年毛利率达到82.6%，同比上涨5.5%，奥布替尼收入的上涨以及单位销售成本的下降。2023年诺诚健华亏损同比收窄。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202403293029302262.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2423032821","title":"诺诚健华2023年营收7.39亿同比增长18.09% 核心技术人员崔霁松薪酬852.54万","url":"https://stock-news.laohu8.com/highlight/detail?id=2423032821","media":"挖贝网","top":-1,"share":"https://www.laohu8.com/m/news/2423032821?lang=zh_cn&edition=full","pubTime":"2024-03-29 09:46","pubTimestamp":1711676803,"startTime":"0","endTime":"0","summary":"挖贝网3月29日，诺诚健华 近日发布2023年度报告，报告期内公司实现营业收入738,537,047.65元，同比增长18.09%；归属于上市公司股东的净利润-631,262,907.71元，上年同期-886,593,114.73元，同比亏损减少。报告期内经营活动产生的现金流量净额为-665,489,513.23元，截至2023年末归属于上市公司股东的净资产7,147,848,684.92元。营业收入较上年同期增加18.09%，主要系奥布替尼销量持续增长所致。公告显示，报告期内董事、监事、高级管理人员报酬合计2,577.82万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403290948118b6ffae0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403290948118b6ffae0&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2422115142","title":"诺诚健华2023年毛利上涨26.6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2422115142","media":"证券时报网","top":-1,"share":"https://www.laohu8.com/m/news/2422115142?lang=zh_cn&edition=full","pubTime":"2024-03-28 22:59","pubTimestamp":1711637967,"startTime":"0","endTime":"0","summary":"2024年3月28日，诺诚健华（香港联交所代码：09969；上交所代码：688428）发布截至2023年12月31日的2023年业绩报告和公司进展。主要财务业绩摘要2023年全年收入同比上涨18.1%，达到7.4亿元（财务业绩摘要中的货币均为人民币），主要是奥布替尼收入同比增长18.5%，达到6.7亿元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202403283028262277.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202403283028262277.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2422189191","title":"诺诚健华2023年实现净利-6.31亿元 同比减亏","url":"https://stock-news.laohu8.com/highlight/detail?id=2422189191","media":"北京商报","top":-1,"share":"https://www.laohu8.com/m/news/2422189191?lang=zh_cn&edition=full","pubTime":"2024-03-28 22:16","pubTimestamp":1711635394,"startTime":"0","endTime":"0","summary":"3月28日晚间，诺诚健华（688428）发布2023年年报显示，2023年公司实现营业收入约7.39亿元，同比增加18.09%；对应实现的归属净利润约为-6.31亿元，上年净利为-8.87亿元，同比实现减亏。诺诚健华表示，报告期内，公司净利较上年同期增加主要系营业收入和利息收入增加、销售费用减少、汇兑损失减少并抵消了研发费用的增长所致。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202403283028235732.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202403283028235732.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2422190449","title":"诺诚健华2023年实现净利-6.31亿元 同比减亏","url":"https://stock-news.laohu8.com/highlight/detail?id=2422190449","media":"北京商报官方账号","top":-1,"share":"https://www.laohu8.com/m/news/2422190449?lang=zh_cn&edition=full","pubTime":"2024-03-28 22:13","pubTimestamp":1711635211,"startTime":"0","endTime":"0","summary":"北京商报讯（记者 丁宁）3月28日晚间，诺诚健华（688428）发布2023年年报显示，2023年公司实现营业收入约7.39亿元，同比增加18.09%；对应实现的归属净利润约为-6.31亿元，上年净利为-8.87亿元，同比实现减亏。诺诚健华表示，报告期内，公司净利较上年同期增加主要系营业收入和利息收入增加、销售费用减少、汇兑损失减少并抵消了研发费用的增长所致。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403282214498b6e1abf&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403282214498b6e1abf&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2422197737","title":"诺诚健华2023年收入7.4亿元 毛利上涨26.6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2422197737","media":"证券时报网","top":-1,"share":"https://www.laohu8.com/m/news/2422197737?lang=zh_cn&edition=full","pubTime":"2024-03-28 22:10","pubTimestamp":1711635058,"startTime":"0","endTime":"0","summary":"3月28日，诺诚健华发布截至2023年12月31日的2023年业绩报告。2023年度收入同比上涨18.1%，达到7.4亿元；毛利同比上涨26.6%，达6.1亿元。公司2023年亏损同比缩窄27.8%，减少至6.5亿元，现金和银行结余截至2023年12月31日为82.2亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202403283028232348.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202403283028232348.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2422219264","title":"诺诚健华(09969)发布年度业绩，经调整亏损4.91亿元 同比增加3.58%","url":"https://stock-news.laohu8.com/highlight/detail?id=2422219264","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2422219264?lang=zh_cn&edition=full","pubTime":"2024-03-28 21:51","pubTimestamp":1711633881,"startTime":"0","endTime":"0","summary":"智通财经APP讯，诺诚健华 发布截至2023年12月31日止年度业绩，该集团取得收益人民币7.39亿元，同比增加18.09%;研发开支7.51亿元，同比增加17.53%;经调整亏损4.91亿元，同比增加3.58%;母公司拥有人应占亏损6.31亿元，同比减少28.8%;每股亏损0.37元。公告称，总收益增加主要归因于奥布替尼的销量持续快速增长。奥布替尼的销售额由截至2022年12月31日止年度的5.66亿元增加18.5%至截至2023年12月31日止年度的6.71亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1095398.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2422919620","title":"财报速递：诺诚健华2023年全年净亏损6.31亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2422919620","media":"新浪财经","top":-1,"share":"https://www.laohu8.com/m/news/2422919620?lang=zh_cn&edition=full","pubTime":"2024-03-28 20:53","pubTimestamp":1711630402,"startTime":"0","endTime":"0","summary":"3月29日，A股上市公司 诺诚健华 发布2023年全年业绩报告。其中，净亏损6.31亿元，亏损同比缩小28.80%。净亏损6.31亿元，亏损同比缩小28.80%从营收和利润方面看，公司本年度实现营业收入7.39亿元，同比增长18.09%，净亏损6.31亿元，亏损同比减少28.80%，基本每股收益为-0.37元。存在3项财务风险根据诺诚健华公布的相关财务信息显示，公司存在3个财务风险，具体如下：指标类型评述盈利营业利润率平均为-40276.04%，公司盈利能力不佳。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403282101338b6de546&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403282101338b6de546&s=b","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"https://cn.innocarepharma.com","stockEarnings":[{"period":"1week","weight":-0.188},{"period":"1month","weight":-0.1594},{"period":"3month","weight":-0.2711},{"period":"6month","weight":-0.2698},{"period":"1year","weight":-0.5744},{"period":"ytd","weight":-0.4107}],"compareEarnings":[{"period":"1week","weight":-0.0298},{"period":"1month","weight":-0.0193},{"period":"3month","weight":0.0598},{"period":"6month","weight":-0.0552},{"period":"1year","weight":-0.2046},{"period":"ytd","weight":-0.0483}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"诺诚健华医药有限公司是一家主要从事生物医药研发、生产和商业化的中国公司。该公司专注于肿瘤和自身免疫性疾病等存在巨大未满足临床需求的领域。该公司的主要产品管线包括奥布替尼、伊布替尼、泽布替尼、Tafasitamab、ICP-490、ICP-B02、ICP-248、ICP-192、ICP-723和ICP-189等。其产品主要用于治疗血液瘤、实体瘤和自身免疫病。该公司还在开发用于治疗由B细胞或T细胞功能异常所导致的自身免疫性疾病的产品。该公司主要在国内和国外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.25,"avgChangeRate":-0.120109},{"month":2,"riseRate":0.5,"avgChangeRate":0.019126},{"month":3,"riseRate":0,"avgChangeRate":-0.043789},{"month":4,"riseRate":0.6,"avgChangeRate":0.092632},{"month":5,"riseRate":0,"avgChangeRate":-0.074217},{"month":6,"riseRate":0.75,"avgChangeRate":0.124297},{"month":7,"riseRate":0.5,"avgChangeRate":-0.026188},{"month":8,"riseRate":0,"avgChangeRate":-0.125366},{"month":9,"riseRate":0,"avgChangeRate":-0.152637},{"month":10,"riseRate":0.5,"avgChangeRate":0.014569},{"month":11,"riseRate":1,"avgChangeRate":0.145409},{"month":12,"riseRate":0.75,"avgChangeRate":0.038159}],"exchange":"SEHK","name":"诺诚健华","nameEN":"INNOCARE"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"诺诚健华(09969)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供诺诚健华(09969)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"诺诚健华,09969,诺诚健华股票,诺诚健华股票老虎,诺诚健华股票老虎国际,诺诚健华行情,诺诚健华股票行情,诺诚健华股价,诺诚健华股市,诺诚健华股票价格,诺诚健华股票交易,诺诚健华股票购买,诺诚健华股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"诺诚健华(09969)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供诺诚健华(09969)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}